Allosteric Bioscience, Inc. Licenses Sarcopenia (Muscle Loss) Prevention/Treatment Technology from Johns Hopkins University

 Allosteric Bioscience, Inc. (ABI) has signed a Licensing Agreement with Johns Hopkins University for treatment and prevention of Sarcopenia, which is loss of muscle mass and function (also called muscle wasting).  It occurs as part of normal aging and is a major side effect of weight loss and diabetes drugs and multiple diseases such as cancer, diabetes, ALS and others. 

The Sarcopenia technology involves inhibition of one of these aging related proteins GCPII. In an animal model, treatment with the inhibitors prevented loss of muscle mass and function (Sarcopenia).  The inhibitors were developed by Dr. Barbara Slusher who is a leading Professor of Neurology (primary), Pharmacology and Molecular Sciences at Johns Hopkins University School of Medicine,  has over 300 scientific publications and is Director of Johns Hopkins Drug discovery.  Prior to joining Johns Hopkins she spent 18 years in the pharmaceutical industry and contributed to development of multiple FDA approved drugs.

This license is an important addition to our Aging/Longevity program designed to Optimize the aging process and Extend Longevity with good health.  Due to this program ABI has the potential for realizing a significant share of the global healthcare market of $1.27 trillion.  We are using Quantum Computers and Advanced AI coupled with genetics, proteomics, genomics and other biological sciences to create modulators of the aging/longevity process.  We have identified several aging related proteins and to make modulators that could control these proteins we have made a library of 4 billion chemicals which have been filtered down to 40 for further analysis in a sponsored research agreement also with Johns Hopkins University under the direction of Dr. Susan Michaelis. 

Dr. Michaelis is a world leader in aging research, a Professor at Johns Hopkins University, School of Medicine and is on the Scientific Advisory Board of ABI.  She has expertise on the genetic aging disease progeria and the proteins progerin and Lamin A which are two aging targets of ABI.  She is quoted as saying “Allosteric Bioscience, Inc. has a unique angle on aging research and aims to improve both lifespan and health span."   

Please contact us for further discussions, including setting up a Zoom meeting to review Allosteric Bioscience Inc new license on prevention and treatment of Sarcopenia, our involvement with Johns Hopkins University and expand on the innovative Aging/Longevity program which has the potential to revolutionize global healthcare.

You may click here to view our company presentation https://allostericbioscience.com/company-presentation/

Forward Looking Statement

The information contained in this communication is for information purposes only and may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements as to future operating results and plans that involve risks and uncertainties. We use words such as “expects”, “anticipates”, “believes”, “estimates”, the negative of these terms and similar expressions to identify forward looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by those projected in the forward-looking statements for any reason. This is neither a solicitation of investment nor an offer to sell and/or buy securities. References herein to “the Company,” “we”, “our,” “us” and similar words or phrases are references to Allosteric Bioscience, Inc., and/or its subsidiaries, unless the context otherwise requires.